← All trials
NCT06908252
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 17, 2025
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Apr 3, 2025
- Last posted
- Sep 23, 2025
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Duke UniversityLead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Duke UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.